Arrowhead Pharmaceuticals (ARWR) Enterprise Value (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Enterprise Value came in at -$1.8 billion in Q1 2026, down 64.08% YoY from -$5.0 billion in Q1 2025, and down 95.07% on a QoQ basis from -$922.3 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Enterprise Value (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Enterprise Value data on file, last reported at -$1.8 billion in Q1 2026.
- Quarterly Enterprise Value fell 64.08% year-over-year to -$1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.8 billion (down 64.08% YoY) and the FY2025 annual result came in at -$882.0 million, down 30.6% from the prior year.
- Enterprise Value eased to -$1.8 billion in Q1 2026, from -$922.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$88.2 million in Q3 2022 to a low of -$1.8 billion in Q1 2026.
- A 5-year average of -$613.8 million and a median of -$482.5 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 71.66% — and 2023, when it slumped 339.76%.
- Tracing ARWR's Enterprise Value over 5 years: stood at -$482.5 million in 2022, then surged by 57.1% to -$207.0 million in 2023, then slumped by 165.4% to -$549.4 million in 2024, then sank by 67.88% to -$922.3 million in 2025, then slumped by 95.07% to -$1.8 billion in 2026.
- The last three Enterprise Value figures came in at -$1.8 billion (Q1 2026), -$922.3 million (Q4 2025), and -$882.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -1.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.60 Bn |
| Mar 31, 2026 | -1.80 Bn |
| Dec 31, 2025 | -922.34 Mn |
| Sep 30, 2025 | -882.00 Mn |
| Jun 30, 2025 | -902.89 Mn |
| Mar 31, 2025 | -1.10 Bn |
| Dec 31, 2024 | -549.40 Mn |
| Sep 30, 2024 | -675.34 Mn |
| Jun 30, 2024 | -428.27 Mn |
| Mar 31, 2024 | -511.49 Mn |
| Dec 31, 2023 | -207.01 Mn |
| Sep 30, 2023 | -387.81 Mn |
| Jun 30, 2023 | -434.58 Mn |
| Mar 31, 2023 | -462.67 Mn |
| Dec 31, 2022 | -482.50 Mn |
| Sep 30, 2022 | -88.19 Mn |
| Jun 30, 2022 | -396.29 Mn |
| Mar 31, 2022 | -208.98 Mn |
| Dec 31, 2021 | -112.54 Mn |
| Sep 30, 2021 | -311.16 Mn |